ELTX · NASDAQ
Elicio Therapeutics, Inc.
$1.86 +0.01 (+0.54%)
Company overview
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002, ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers, ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers, ELI-005, a vaccine candidate for the prevention of COVID-19, ELI-011 for the treatment of hematological cancers, and ELI-012, an mKRAS TCR T cell amplifier designed to be used in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $35.5M
- Employees
- 32
- Headquarters
- Boston, MA
- Website
- elicio.com
- CEO
- Robert T. Connelly
- Listed
- February 5, 2021
- P/E
- -0.79
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$289,000
- Operating income
- -$37.6M
- EBITDA
- -$36.9M
- Net income
- -$40.2M
- EPS
- -$2.36
- Total assets
- $22.7M
- Total debt
- $4.9M
- Earnings yield
- -126.88%
ELTX
1D
NASDAQ
O1.80H1.89L1.72C1.85+0.02 (+1.09%)Vol63.48K